Abstract
In the era of ‘treat-to-target’ management of inflammatory bowel disease (IBD), non-invasive methods of disease assessment are increasingly utilised. The rising incidence of IBD in newly industrialised countries poses additional challenges where access to ‘traditional’ methods of disease assessment, such as ileocolonoscopy, is more limited due to resource constraints. Intestinal ultrasound (IUS) provides a real-time assessment of transmural inflammation and is useful for proactive and reactive monitoring of IBD. Despite this, IUS is limited by inter-operator variability, the need for specialised training, and relatively limited worldwide availability.